{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:54:57Z","timestamp":1761562497851,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.carrev.2018.07.029","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T22:05:28Z","timestamp":1533247528000},"page":"956-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Planned use of GP IIb\/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold"],"prefix":"10.1016","volume":"19","author":[{"given":"David B.","family":"Jessup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew M.","family":"Grove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2018.07.029_bb0005","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcin.2012.02.017","volume":"5","author":"Gogas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0010","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/eurheartj\/ehr466","volume":"33","author":"Brugaletta","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.07.029_bb0015","first-page":"996","article-title":"Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities","volume":"11","author":"Simsek","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2018.07.029_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCINTERVENTIONS.113.000987","article-title":"Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5\u20137\u202fyears) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2","volume":"7","author":"Natsuaki","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0025","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3\u202fyears after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial","volume":"380","author":"Camenzind","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.07.029_bb0030","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.ijcard.2013.03.046","article-title":"Incidence and predictors of the late catch-up phenomenon after drug-eluting stent implantation","volume":"168","author":"Iijima","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0035","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jcin.2013.07.009","volume":"6","author":"Gada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jcin.2015.03.028","volume":"8","author":"Smits","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0045","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.jacc.2013.12.036","volume":"63","author":"Taniwaki","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcin.2014.10.005","volume":"8","author":"Brugaletta","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0055","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3\u202fyear, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.07.029_bb0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5603\/CJ.a2016.0052","article-title":"Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: a propensity score-matched analysis from a multicenter \u201creal-world\u201d registry","volume":"23","author":"Imori","year":"2016","journal-title":"Cardiol J"},{"key":"10.1016\/j.carrev.2018.07.029_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","article-title":"Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials","volume":"387","author":"Cassese","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.07.029_bb0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","article-title":"Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis","volume":"9","author":"Lipinski","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0075","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jcin.2015.02.011","article-title":"Impact of strut width in periprocedural myocardial infarction: a propensity-matched comparison between bioresorbable scaffolds and the first-generation sirolimus-eluting stent","volume":"8","author":"Kawamoto","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0080","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2018.07.029_bb0085","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease","volume":"373","author":"Ellis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2018.07.029_bb0090","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1016\/j.jacc.2016.03.576","article-title":"The contemporary pulse of bioresorbable-scaffold thrombosis among expert operators","volume":"67","author":"Cortese","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/joic.12297","article-title":"Bioresorbable vascular scaffolds in a real-world patient population-results from a mid-term angiographic follow-up","volume":"29","author":"Saad","year":"2016","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0100","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","article-title":"Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors","volume":"67","author":"Puricel","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4244\/EIJV10I5A103","article-title":"Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?","volume":"10","author":"Fernandez-Rodriguez","year":"2014","journal-title":"EuroIntervention"},{"key":"10.1016\/j.carrev.2018.07.029_bb0110","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/eurheartj\/ehu419","article-title":"Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy","volume":"36","author":"Timmers","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2018.07.029_bb0115","series-title":"Draft definitions for CDISC","first-page":"1","article-title":"Standardized definitions for cardiovascular and stroke end point events in clinical trials","author":"Hicks","year":"2014"},{"key":"10.1016\/j.carrev.2018.07.029_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","volume":"385","author":"Serruys","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.07.029_bb0125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2018.07.029_bb0130","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/j.1538-7836.2009.03573.x","article-title":"Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction","volume":"7","author":"Heestermans","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.carrev.2018.07.029_bb0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","article-title":"Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction","volume":"5","author":"Alexopoulos","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0140","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1160\/TH15-02-0149","article-title":"Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome","volume":"114","author":"Bonello","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.carrev.2018.07.029_bb0145","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","article-title":"Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study","volume":"61","author":"Parodi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0150","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","article-title":"Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction","volume":"122","author":"Heestermans","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.carrev.2018.07.029_bb0155","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1160\/TH12-02-0125","article-title":"Biological efficacy of a 600\u202fmg loading dose of clopidogrel in ST-elevation myocardial infarction","volume":"108","author":"Bonello","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.carrev.2018.07.029_bb0160","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.amjcard.2005.09.080","article-title":"Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb\/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention","volume":"97","author":"Danzi","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0165","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.ahj.2007.05.007","article-title":"Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study","volume":"154","author":"Mardikar","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2018.07.029_bb0170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2004.02.059","article-title":"Ability of anti-glycoprotein IIb\/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions","volume":"44","author":"Goto","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","article-title":"Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates","volume":"41","author":"Moser","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0180","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jcin.2015.04.031","article-title":"Impact of glycoprotein IIb\/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry","volume":"8","author":"Safley","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0185","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2008.09.060","article-title":"Abbreviated infusion of eptifibatide after successful coronary intervention. The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial","volume":"53","author":"Fung","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2018.07.029_bb0190","doi-asserted-by":"crossref","first-page":"e001880","DOI":"10.1161\/CIRCINTERVENTIONS.114.001880","article-title":"Comparative effectiveness and safety of a catheterization laboratory-only eptifibatide dosing strategy in patients undergoing percutaneous coronary intervention","volume":"8","author":"Gurm","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2018.07.029_bb0195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2016.01.202","article-title":"Bioresorbable scaffold vs. second generation drug eluting stent in long coronary lesions requiring overlap: a propensity-matched comparison (the UNDERDOGS study)","volume":"208","author":"Biscaglia","year":"2016","journal-title":"Int J Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918303282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838918303282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:30Z","timestamp":1761560130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838918303282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1553838918303282"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2018.07.029","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Planned use of GP IIb\/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2018.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}